Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025

Core Insights - Inozyme Pharma is presenting data on INZ-701, an enzyme replacement therapy for ENPP1 Deficiency, at the CHOP Cardiology Annual Meeting [1][2] - ENPP1 Deficiency is a rare and serious disease affecting blood vessels and bones, with no approved therapies currently available [2][3] Company Overview - Inozyme Pharma is a clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases impacting bone health and blood vessel function [3][4] - The company specializes in the PPi-Adenosine Pathway, which is crucial for regulating mineralization and controlling smooth muscle cell proliferation in blood vessels [3] Product Information - INZ-701 is an ENPP1 Fc fusion protein designed to increase levels of inorganic pyrophosphate (PPi) and adenosine, potentially treating multiple diseases linked to deficiencies in these molecules [4] - The therapy is currently in clinical development for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis, aiming to address significant morbidity and mortality associated with these conditions [4]